TY - JOUR T1 - Clinical Outcomes of Scanning Carbon-ion Radiotherapy for Soft Tissue Sarcoma of the Extremities JF - Anticancer Research JO - Anticancer Res SP - 3701 LP - 3706 DO - 10.21873/anticanres.15859 VL - 42 IS - 7 AU - YOSUKE TAKAKUSAGI AU - ITSUKO SERIZAWA AU - HIROAKI KOGE AU - KIO KANO AU - SATOSHI SHIMA AU - KEISUKE TSUCHIDA AU - NOBUTAKA MIZOGUCHI AU - DAISAKU YOSHIDA AU - HIROYUKI KATOH AU - TORU HIRUMA AU - TADASHI KAMADA Y1 - 2022/07/01 UR - http://ar.iiarjournals.org/content/42/7/3701.abstract N2 - Background/Aim: Carbon-ion radiotherapy (CIRT) has been reported to obtain favorable results in the treatment of bone and soft tissue malignancies; however, studies on CIRT for soft tissue sarcomas (STS) of the extremities are limited. Here, we have retrospectively evaluated the therapeutic efficacy and adverse events associated with scanning CIRT (sCIRT) for STS of the extremities at our institution. Patients and Methods: Thirteen consecutive patients with STS who underwent sCIRT between January 2017 and January 2020 were included in the study. The total dose of sCIRT was set at 67.2-70.4 Gy (RBE), which was provided in 16 fractions. Overall survival (OS), progression-free survival (PFS), and local control (LC) were estimated using the Kaplan–Meier method. Toxicity was evaluated using Common Terminology Criteria for Adverse Events v5.0. Results: The cohort consisted of 10 males and 3 females with a median age of 69 years (range=38-95 years). Median duration of observation was 31.8 months (range=7.4-56.4 months). Tumors were localized to the upper extremity in 2 cases and to the lower extremity in 11 cases. Median maximum tumor diameter was 11.7 cm (range=3.0-36.6 cm), while 3-year OS, PFS, and LC were 61.5%, 44.9%, and 79.1%, respectively. Acute toxicity of grade 3 or higher was not observed. Late toxicity included grade 3 peripheral nerve palsy and decreased range of motion in 1 and 1 patient each. Late toxicity of Grade 4 or higher was not observed. Conclusion: sCIRT for STS of the extremities demonstrates favorable therapeutic results with acceptable toxicity. ER -